The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01).
M. Ahn
No relevant relationships to disclose
J. Sun
No relevant relationships to disclose
J. S. Ahn
No relevant relationships to disclose
S. Kim
No relevant relationships to disclose
K. H. Lee
No relevant relationships to disclose
Y. J. Min
No relevant relationships to disclose
H. J. Yun
No relevant relationships to disclose
H. Kim
No relevant relationships to disclose
H. Song
No relevant relationships to disclose
Y. H. Kim
No relevant relationships to disclose
B. Kim
No relevant relationships to disclose
I. G. Hwang
No relevant relationships to disclose
K. Lee
No relevant relationships to disclose
I. S. Woo
No relevant relationships to disclose
H. Ryoo
No relevant relationships to disclose
K. H. Lee
No relevant relationships to disclose
H. G. Yi
No relevant relationships to disclose
J. Jang
No relevant relationships to disclose
J. H. Kwon
No relevant relationships to disclose
K. Park
No relevant relationships to disclose